Receptors, Tumor Necrosis Factor
"Receptors, Tumor Necrosis Factor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Cell surface receptors that bind TUMOR NECROSIS FACTORS and trigger changes which influence the behavior of cells.
MeSH Number(s)
D12.776.543.750.705.852.760
Concept/Terms
Receptors, Tumor Necrosis Factor- Receptors, Tumor Necrosis Factor
- Receptors, Cachectin
- Tumor Necrosis Factor Receptors
- TNF Receptor
- Receptor, TNF
- TNF Receptors
- Tumor Necrosis Factor Receptor
- Cachectin Receptors
- Receptors, TNF
Below are MeSH descriptors whose meaning is more general than "Receptors, Tumor Necrosis Factor".
Below are MeSH descriptors whose meaning is more specific than "Receptors, Tumor Necrosis Factor".
- Receptors, Tumor Necrosis Factor
- Antigens, CD137
- Antigens, CD27
- Antigens, CD30
- Antigens, CD40
- Antigens, CD95
- B-Cell Activation Factor Receptor
- B-Cell Maturation Antigen
- Glucocorticoid-Induced TNFR-Related Protein
- Lymphotoxin beta Receptor
- Receptor Activator of Nuclear Factor-kappa B
- Receptors, Ectodysplasin
- Receptors, OX40
- Receptors, TNF-Related Apoptosis-Inducing Ligand
- Receptors, Tumor Necrosis Factor, Member 14
- Receptors, Tumor Necrosis Factor, Member 25
- Receptors, Tumor Necrosis Factor, Type I
- Receptors, Tumor Necrosis Factor, Type II
- Transmembrane Activator and CAML Interactor Protein
- Tumor Necrosis Factor Decoy Receptors
This graph shows the total number of publications written about "Receptors, Tumor Necrosis Factor" by people in Harvard Catalyst Profiles by year, and whether "Receptors, Tumor Necrosis Factor" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 0 | 2 | 2 |
| 1994 | 2 | 1 | 3 |
| 1995 | 4 | 2 | 6 |
| 1996 | 6 | 4 | 10 |
| 1997 | 7 | 5 | 12 |
| 1998 | 6 | 5 | 11 |
| 1999 | 19 | 10 | 29 |
| 2000 | 7 | 10 | 17 |
| 2001 | 17 | 16 | 33 |
| 2002 | 13 | 20 | 33 |
| 2003 | 19 | 18 | 37 |
| 2004 | 10 | 23 | 33 |
| 2005 | 14 | 23 | 37 |
| 2006 | 15 | 15 | 30 |
| 2007 | 4 | 14 | 18 |
| 2008 | 8 | 9 | 17 |
| 2009 | 2 | 9 | 11 |
| 2010 | 13 | 5 | 18 |
| 2011 | 4 | 8 | 12 |
| 2012 | 6 | 10 | 16 |
| 2013 | 8 | 7 | 15 |
| 2014 | 4 | 4 | 8 |
| 2015 | 2 | 3 | 5 |
| 2016 | 1 | 0 | 1 |
| 2017 | 1 | 1 | 2 |
| 2018 | 2 | 0 | 2 |
| 2019 | 0 | 1 | 1 |
| 2020 | 1 | 1 | 2 |
| 2021 | 1 | 0 | 1 |
| 2022 | 0 | 2 | 2 |
Below are the most recent publications written about "Receptors, Tumor Necrosis Factor" by people in Profiles.
-
Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney and heart failure outcomes guided by HbA1c, albuminuria, and predicted risk of kidney failure. Cardiovasc Diabetol. 2022 09 23; 21(1):194.
-
Galectin-3 Decreases 4-1BBL Bioactivity by Crosslinking Soluble and Membrane Expressed 4-1BB. Front Immunol. 2022; 13:915890.
-
Effect of TNFa stimulation on expression of kidney risk inflammatory proteins in human umbilical vein endothelial cells cultured in hyperglycemia. Sci Rep. 2021 05 27; 11(1):11133.
-
A profile of multiple circulating tumor necrosis factor receptors associated with early progressive kidney decline in Type 1 Diabetes is similar to profiles in autoimmune disorders. Kidney Int. 2021 03; 99(3):725-736.
-
On the TRAIL of Better Therapies: Understanding TNFRSF Structure-Function. Cells. 2020 03 20; 9(3).
-
Death Receptor 6 (DR6) Is Overexpressed in Astrocytomas. Anticancer Res. 2019 May; 39(5):2299-2306.
-
A signature of circulating inflammatory proteins and development of end-stage renal disease in diabetes. Nat Med. 2019 05; 25(5):805-813.
-
Daily Rhythms of TNFa Expression and Food Intake Regulate Synchrony of Plasmodium Stages with the Host Circadian Cycle. Cell Host Microbe. 2018 06 13; 23(6):796-808.e6.
-
Curcumin enhances the anti-cancer effects of Paris Saponin II in lung cancer cells. Cell Prolif. 2018 Aug; 51(4):e12458.
-
Tumor necrosis factor receptor signaling is a driver of chronic lymphocytic leukemia that can be therapeutically targeted by the flavonoid wogonin. Haematologica. 2018 04; 103(4):688-697.